We previously reported that the TIL status influences the clinical outcomes of anti–PD-1/PD-L1 therapy, even in patients with advanced NSCLC with tumors exhibiting high PD-L1 expression.28 This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.